CATAPULT THERAPEUTICS

Catapult Therapeutics is a clinical-stage biopharmaceutical company developing CAP-100 - an anti-CCR7 antibody with a unique mechanism of action interfering with the fundamental pathology of hematological malignancies. Catapult's phase I clinical trial is currently performed at Dana-Farber Cancer Institute in Boston and three other leading clinical sites in the USA. An expansion to the study to Europe is planned for fall 2022... Catapult Therapeutics was established in 2015 as a Dutch privately held joint venture between Spanish and Dutch partners. Catapult is founded on the discoveries of Dr Cecilia Munoz and her group at Hospital La Princesa in Madrid. They identified and validated CCR7 as a therapeutic target for leukemias and lymphomas. Technology of Dutch biotech company Pepscan made it possible to generate antibodies against human CCR7... Catapult Therapeutics is led by an experienced team of managers and scientists from the Netherlands and Spain. Catapult Therapeutics was..

Also known as: Catapult Therapeutics B.V.

Primary location: Lelystad Netherlands